Axillary lymph node status remains an important prognostic factor in early breast cancer. It is regarded as an indicator for (neo)adjuvant systemic treatment and postoperative radiotherapy of the regional lymphatics. Commenced in September 2015, the INSEMA trial is investigating whether operative determination of nodal status as part of breast conserving therapy (BCT) for early stage breast can...

PURPOSE: Head and neck melanoma is associated with a high false negative sentinel lymph node biopsy (SLNB) rate. Our group previously demonstrated the combination of radiotracer and ICG SPY Elite navigation system was feasible and more sensitive compared to standard vital dye and radioactive tracer for SLNB. The goal of this report was to analyze our experiences utilizing ICG fluorescence with ...

Sentinel lymph node biopsy (SLNB) has been explored as a method to determine the need for axillary lymph node dissection (ALND) in breast cancer patients. In theory, a properly performed negative SLNB should accurately identify those patients without axillary node involvement, thereby obviating the need for a more morbid ALND. The risk of arm morbidity, particularly lymphedema, chronic pain, sh...

Aim. to compare (18)F-Fluorodeoxyglucose positron emission tomography (FDG-PET) to sentinel lymph node biopsy (SLNB) for regional lymph nodal staging in patients with melanoma. Methods. We performed a literature review discussing original articles which compared FDG-PET to SLNB for regional lymph nodal staging in patients with melanoma. Results and Conclusions. There is consensus in the literat...

Axillary lymph node surgery remains an integral component of breast cancer treatment. Node status provides key prognostic information that is used to direct adjuvant systemic therapy (1). Removal of the nodes may also improve local control, although the preponderance of data shows no survival advantage with node dissection itself (2). Until recently, surgery required full axillary lymph node di...

PURPOSE/OBJECTIVES To evaluate prevalence, severity, and level of distress of 18 sensations at 3-15 days (baseline), 3 months, and 6 months after breast cancer surgery; to compare sentinel lymph node biopsy (SLNB) to SLNB with immediate or delayed axillary lymph node dissection; to evaluate the Breast Sensation Assessment Scale(c) (BSAS(c)) for reliability and validity. DESIGN Prospective, de...

Sentinel lymph node biopsy (SLNB) is an appropriate method for the evaluation of axillary status in cases of early breast cancer. We report our experience in treating cases evaluated using SLNB. We analyzed a total of 1192 cases assessed by means of SLNB from July 1999 to December 2007. SLNB processing was successfully completed in 1154 cases with the use of blue dye or radiolabeled 99mTc-Dextr...

Sentinel lymph node biopsy (SLNB) provides an accurate staging tool for a variety of malignancies including urological cancers. Initially introduced as a single procedure technique, SLNB has evolved into a dynamic multi-stage procedure that has an invaluable impact on the management of cancer patients. After a thorough literature search, this article summarises the advancement of the SLNB proce...

BACKGROUND This study investigated survival probabilities and prognostic factors in sentinel lymph node biopsy (SLNB) staged patients with cutaneous melanoma (CM) with the aim of defining subgroups of patients who are at higher risk for recurrences and who should be considered for adjuvant clinical trials. METHODS Patients with primary CM who underwent SLNB in the Department of Dermatology, U...

PURPOSE During a sentinel lymph node biopsy (SLNB) for breast cancer, the appropriate number of sentinel lymph nodes (SLNs) to be removed for accurate axillary staging is still controversial. We hypothesized that there might be an optimal threshold number of SLNs. We investigated how many SLNs should be removed to achieve an acceptable accuracy and ensure minimal morbidity. METHODS We reviewe...